globenewswire.com · 25 jun

EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis

Hannover, Germany, June 25, 2026 (GLOBE NEWSWIRE) -- EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis —Long-Term, Open-Label Study to Enroll Approximately 3,000 Patients Across Europe—

prnewswire.com · 23 jun

Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory

BRIDGEWATER, N.J., June 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the appointment of Samuele Butera as Senior Vice President, General Manager, Global Respiratory, effective today.

etftrends.com · 22 jun

The Qs Shift Gears: Nasdaq 100 Rebalances While SpaceX Looms

The Nasdaq 100 implemented its June quarterly rebalance, which shifts the tide for “the Qs.” Namely, the Invesco QQQ Trust (QQQ) and its cost-efficient sibling, the Invesco Nasdaq 100 ETF (QQQM).

seekingalpha.com · 22 jun

Insmed: Extensive Phase 3 TPIP Program And Revenue Growth In Q1 2026, Strong Buy

Insmed is maintained at "Strong Buy" due to robust pipeline progress and expanding commercial execution. INSM's key catalysts include ARIKAYCE's sNDA submission for 1st-line MAC Lung Disease in H2 2026 and ongoing regulatory expansion efforts in Japan. TPIP advances with phase 3 PALM-PAH and PALM-ILD studies, targeting large PAH and PH-ILD markets with potential best-in-class, once-daily dosing.

globenewswire.com · 11 jun

Nasdaq-100 Index® June 2026 Quarterly Changes

NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the June 2026 quarterly rebalance of the Nasdaq-100 Index (NDX), which will become effective prior to market open on Monday, June 22, 2026. The following five companies will be added to the Index: Astera Labs, Inc.

seekingalpha.com · 9 jun

Insmed Incorporated (INSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Insmed Incorporated (INSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

prnewswire.com · 4 jun

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J., June 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 103 new employees.

prnewswire.com · 27 may

Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference

BRIDGEWATER, N.J., May 27, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 2026 Goldman Sachs Annual Global Healthcare Conference in Miami on Tuesday, June 9, 2026, at 10:00 a.m.